Vaccinex, Inc. (VCNX)

NASDAQ: VCNX · IEX Real-Time Price · USD
1.04 -0.05 (-4.59%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap32.03M
Revenue (ttm)900,000
Net Income (ttm)-24.19M
Shares Out30.80M
EPS (ttm)-0.91
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume80,090
Open1.07
Previous Close1.09
Day's Range1.03 - 1.08
52-Week Range1.02 - 9.56
Beta1.54
AnalystsBuy
Price Target7.00 (+573.1%)
Earnings Daten/a

About VCNX

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alz...

IndustryBiotechnology
Founded2001
Employees39
Stock ExchangeNASDAQ
Ticker SymbolVCNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for Vaccinex stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 573.08% from the latest price.

Price Target
$7.00
(573.08% upside)
Analyst Consensus: Buy

News

Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurre...

Phase 1b segment evaluated safety and tolerability of the combination

2 weeks ago - GlobeNewsWire

Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

In-person and virtual Presentation: November 10-14th, 2021 In-person and virtual Presentation: November 10-14th, 2021

2 months ago - GlobeNewsWire

Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer's Disease (CTAD) Meeting

Live Presentation: Thursday, Nov. 11, 2021 Live Presentation: Thursday, Nov. 11, 2021

2 months ago - GlobeNewsWire

Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Enrollment underway in combination Phase 1b/2 study of pepinemab with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

2 months ago - GlobeNewsWire

Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference

Virtual Dates: November 18 th – 19 th , 2021

2 months ago - GlobeNewsWire

Vaccinex to Present at the Virtual Huntington's Study Group Meeting on November 4-6, 2021

Presentation to highlight expanded post-hoc subgroup analysis of the SIGNAL Phase 2 Huntington's Disease (HD) trial suggesting a cognitive benefit in patients with mildly advanced disease Presentation t...

2 months ago - GlobeNewsWire

Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit

ROCHESTER, N.Y., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and c...

4 months ago - GlobeNewsWire

Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Patients are currently being screened and enrolled in two studies of pepinemab as monotherapy in Alzheimer's disease and in combination with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcinoma...

5 months ago - GlobeNewsWire

Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease

ROCHESTER, N.Y., June 30, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and ca...

6 months ago - GlobeNewsWire

Vaccinex Initiates Pepinemab Trials for Alzheimer's, Head & Neck Cancer

Vaccinex Inc (NASDAQ: VCNX) has activated first clinical sites to screen and enroll patients in its Phase 1/2 study evaluating pepinemab as a single agent in Alzheimer's disease (AD) and in its phase 2 ...

7 months ago - Benzinga

Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheim...

Company plans to activate at least 13 clinical sites for Alzheimer's study and 18 clinical sites for head and neck cancer across the United States Company plans to activate at least 13 clinical sites fo...

7 months ago - GlobeNewsWire

Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update

Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic head and neck cancer

8 months ago - GlobeNewsWire

Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer...

CLASSICAL-Lung study evaluated pepinemab in combination with the checkpoint inhibitor BAVENCIO® for the treatment of non-small cell lung cancer CLASSICAL-Lung study evaluated pepinemab in combination wi...

9 months ago - GlobeNewsWire

Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update

Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab in neurodegenerative disease. New Alzheimer's study expected to begin enrollment in Q2

10 months ago - GlobeNewsWire

Why Novavax, Vaccinex, Evolus Are Trading Higher Today

Novavax (NASDAQ: NVAX) shares are trading higher Friday after the company announced a Memorandum of Understanding with Gavi to provide 1.1 billion cumulative doses of NVX-CoV2373. Novavax is a biotechno...

Other symbols:EOLSNVAX
11 months ago - Benzinga

Vaccinex stock soars 223% on partnership deals using its antibody discovery platform (VCNX)

Vaccinex stock rocketed up more than 200% Friday, propelled by two collaboration deals centered on using the biotech company's antibody discovery platform.  Vaccinex, which focuses on cancer and neurode...

11 months ago - Business Insider

Vaccinex's stock soars toward record gain on record volume after deals with 'prominent' drug makers

Shares of Vaccinex Inc. soared toward a record rally on record volume Friday, after the biotechnology company announced the signing of multiple-project deals with two "prominent" pharmaceutical companie...

11 months ago - Market Watch

VCNX Stock: 11 Things to Know About Vaccinex and the Deals That Have Shares Soaring

Vaccinex (VCNX) stock is rocketing higher on Friday after following an announcement about multi-project deals with two comapnies. The post VCNX Stock: 11 Things to Know About Vaccinex and the Deals That...

11 months ago - InvestorPlace

Why Vaccinex Shares Are Rallying

Shares of micro-cap biopharma Vaccinex Inc (NASDAQ: VCNX) were trading higher Friday on above-average volume. Rochester, New York-based Vaccinex, which focuses on therapies for cancer and neurodegenerat...

11 months ago - Benzinga

Vaccinex Rallies After Announcing Multi-Project Pact Using Its Antibody Discovery Platform

Vaccinex Inc (NASDAQ: VCNX) jumps premarket in reaction to multi-project deals signed with two undisclosed prominent pharmaceutical companies, utilizing Vaccinex's ActivMAb, antibody discovery, and nove...

11 months ago - Benzinga

Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its...

Partnerships will use Vaccinex's ActivMAb® platform for viral display of complex antigens to enable antibody discovery Partnerships will use Vaccinex's ActivMAb® platform for viral display of complex an...

11 months ago - GlobeNewsWire

Bet on Rising P/E With These 5 Top-Ranked Stocks

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other symbols:BJBLCMLMNLQFINVIVO
1 year ago - Zacks Investment Research

Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative dis...

1 year ago - GlobeNewsWire

Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Addition al data from SIGNAL Huntington's disease (HD) trial support continued development in H D and in Alzheimer's disease (AD)

1 year ago - GlobeNewsWire

CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference

SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington's disease

1 year ago - GlobeNewsWire